DMAAR · Drugs Made In America Acquisition Corp.
Substantial doubt about the company's ability to continue as a going concern.
“Additionally, the date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Management plans to address this uncertainty through a Business Combination. There is no assurance that the Company’s plans to raise capital or to consummate a Business Combination will be successful within the Combination Period.”View the 10-Q filed Aug 14, 2026
Price & Indicators
The closing range uses available history since Jul 23, 2026; less than a full year is stored.
Latest filings
Drugs Made In America Acquisition Corp. amended its PAGC merger, automatically reducing the valuation to US$1,710,000,000 if APQC Acquisition misses November 1, 2026; Joel A. Gallo is expected to deliver the fairness opinion by October 26, 2026.
Read the 8-KTechnicals
trend & momentum for long-term holders illustrative — not investment adviceIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DMAAR
this stock
Drugs Made In America Acquisition Corp.
|
$264.13M | — | — | — | — |
|
VYLR
Vylor Inc.
|
$49.34B | — | — | — | 2.2% |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$649.42M | +3.0% | — | — | 0.2% |
|
EVAC
EQV Ventures Acquisition Corp. II
|
$604.35M | +3.2% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 21, 2026
- This year
- 17
Drugs Made In America Acquisition Corp. amended its PAGC merger, automatically reducing the valuation to US$1,710,000,000 if APQC Acquisition misses November 1, 2026; Joel A. Gallo is expected to deliver the fairness opinion by October 26, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DMAAR | -8.1% | -13.5% | — | -12.4% | — |
| SPY | +0.1% | +0.7% | +4.9% | +0.9% | +12.9% |
| vs SPY | -8.2% | -14.2% | — | -13.3% | — |